Cover Image
市場調查報告書

代謝化學試劑 - 開發中產品分析

Metabolite Chemistry Reagents - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 344266
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
代謝化學試劑 - 開發中產品分析 Metabolite Chemistry Reagents - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年09月01日 內容資訊: 英文 90 Pages
簡介

本報告提供代謝化學試劑的開發中產品調查分析,提供您主要開發中產品,主要企業,各開發階段的開發中產品,主要的臨床實驗資料,最近的趨勢等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 代謝化學試劑概要

第3章 開發中的產品

  • 代謝化學試劑 - 開發中產品:各開發階段
  • 代謝化學試劑 - 開發中產品:各地區
  • 代謝化學試劑 - 開發中產品:各法規途徑
  • 代謝化學試劑 - 開發中產品:各核准時期 (預定)
  • 代謝化學試劑 - 進行中的臨床試驗

第4章 代謝化學試劑:正在開發的開發中產品 (各企業)

  • 代謝化學試劑企業 - 開發中產品:各開發階段
  • 代謝化學試劑 - 開發中產品:各開發階段

第5章 代謝化學試劑企業與產品概要

  • A/C Diagnostics LLC
  • Abbott Diagnostics
  • Alfa Wassermann Diagnostic Technologies, LLC
  • Analyticon Biotechnologies AG
  • Axis-Shield Limited (暫停中)
  • Beckman Coulter, Inc.
  • BG Medicine, Inc.
  • Boulder Diagnostics Inc.
  • Consejo Superior de Investigaciones Cientificas
  • Genesis Detection Systems, Inc.
  • Healthmed Services Ltd.
  • Illumina, Inc.
  • Instrumentation Laboratory Company
  • iXensor Co. Ltd.
  • Miraculins Inc.
  • Molecular Biometrics, LLC.
  • Ohmx Corporation
  • Oxford Immunotec Limited
  • Randox Laboratories Limited
  • Sekisui Medical Co., Ltd.
  • SenGenix, Inc.
  • Siemens Healthcare Diagnostics Inc.
  • The Binding Site Group Ltd.
  • Vital Diagnostics, Inc.

第6章 代謝化學試劑:最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0427EPD

GlobalData's Medical Devices sector report, "Metabolite Chemistry Reagents - Medical Devices Pipeline Assessment, 2017" provides an overview of Metabolite Chemistry Reagents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metabolite Chemistry Reagents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Metabolite Chemistry Reagents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Metabolite Chemistry Reagents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Metabolite Chemistry Reagents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Metabolite Chemistry Reagents Overview 6

3 Products under Development 7

  • 3.1 Metabolite Chemistry Reagents - Pipeline Products by Stage of Development 7
  • 3.2 Metabolite Chemistry Reagents - Pipeline Products by Territory 8
  • 3.3 Metabolite Chemistry Reagents - Pipeline Products by Regulatory Path 9

4 Metabolite Chemistry Reagents - Pipeline Products under Development by Companies 10

  • 4.1 Metabolite Chemistry Reagents Companies - Pipeline Products by Stage of Development 10
  • 4.2 Metabolite Chemistry Reagents - Pipeline Products by Stage of Development 11

5 Metabolite Chemistry Reagents Companies and Product Overview 12

  • 5.1 A/C Diagnostics LLC Company Overview 12
    • 5.1.1 A/C Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 12
  • 5.2 Advanced Liquid Logic Inc Company Overview 13
    • 5.2.1 Advanced Liquid Logic Inc Pipeline Products & Ongoing Clinical Trials Overview 13
  • 5.3 Alfa Wassermann Diagnostic Technologies, LLC Company Overview 14
    • 5.3.1 Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.4 Analyticon Biotechnologies AG Company Overview 15
    • 5.4.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.5 BG Medicine Inc Company Overview 33
    • 5.5.1 BG Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.6 Genesis Detection Systems, Inc. Company Overview 34
    • 5.6.1 Genesis Detection Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.7 Healthmed Services Ltd. (Inactive) Company Overview 35
    • 5.7.1 Healthmed Services Ltd. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.8 Instrumentation Laboratory Company Company Overview 36
    • 5.8.1 Instrumentation Laboratory Company Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.9 iXensor Co. Ltd. Company Overview 37
    • 5.9.1 iXensor Co. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.10 Luminor Medical Technologies Inc Company Overview 38
    • 5.10.1 Luminor Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.11 Ohmx Corp Company Overview 39
    • 5.11.1 Ohmx Corp Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.12 Siemens Healthcare GmbH Company Overview 40
    • 5.12.1 Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.13 The Binding Site Group Ltd Company Overview 41
    • 5.13.1 The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.14 Versantis AG Company Overview 42
    • 5.14.1 Versantis AG Pipeline Products & Ongoing Clinical Trials Overview 42

6 Metabolite Chemistry Reagents- Recent Developments 43

  • 6.1 Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 43
  • 6.2 Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 44
  • 6.3 Jul 28, 2017: Merck Announces Second-Quarter 2017 Financial Results 45
  • 6.4 Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 47
  • 6.5 Jul 17, 2017: Governor Abbott Announces Merck IT Hub In Austin 50
  • 6.6 Jul 03, 2017: Premaitha Health Litigation Update 50
  • 6.7 Jun 21, 2017: Immunodiagnostic Systems Holdings: Final Results for year ended 31 March 2017 51
  • 6.8 May 22, 2017: Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role 52
  • 6.9 May 18, 2017: Aalto Bio Reagents Launches West Nile Virus Native and Recombinant Proteins for Diagnostic Testing 52
  • 6.10 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 53
  • 6.11 May 02, 2017: Oxford Immunotec Reports First Quarter 2017 Financial Results 55
  • 6.12 Apr 25, 2017: Illumina Reports Financial Results for First Quarter of Fiscal Year 2017 56
  • 6.13 Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 57
  • 6.14 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 60
  • 6.15 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 60
  • 6.16 Mar 31, 2017: HORIBA Instruments commences operations at new factory in Houston 61
  • 6.17 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 62
  • 6.18 Mar 20, 2017: EKF Diagnostics Holdings: Final results 62
  • 6.19 Mar 13, 2017: Immunodiagnostic Systems Holdings Re-Appoints CEO 63
  • 6.20 Feb 24, 2017: Immunodiagnostic Systems Holdings: Update on CEO Appointment 63
  • 6.21 Feb 20, 2017: Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina 63
  • 6.22 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 64
  • 6.23 Jan 31, 2017: Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016 66
  • 6.24 Jan 27, 2017: Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries 67
  • 6.25 Jan 27, 2017: Omega Diagnostics Group: Update on discussions with Immunodiagnostic Systems Holdings 68
  • 6.26 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 68
  • 6.27 Jan 19, 2017: Immunodiagnostic Systems Holdings Announces Directorate Change 69
  • 6.28 Jan 03, 2017: Illumina Taps Garret Hampton, One of the World's Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit 69
  • 6.29 Dec 22, 2016: Bionaturis Group gets a new patent in USA innovating in the use of natural resources to produce pharmaceutical products 70
  • 6.30 Dec 20, 2016: Illumina Names Jonathan Seaton as Senior Vice President for Corporate & Business Development, Adding Further Clinical and Life Sciences Expertise to its Executive Team 70
  • 6.31 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe 70
  • 6.32 Dec 14, 2016: Siemens Healthineers to significantly expand its Walpole, Mass. Laboratory Diagnostic manufacturing facility 71
  • 6.33 Dec 07, 2016: Illumina appoints senior vice president and CFO 72
  • 6.34 Dec 07, 2016: Illumina Extends Management Team, Appoints Sam A. Samad as Senior Vice President and Chief Financial Officer 72
  • 6.35 Nov 25, 2016: Immunodiagnostic Systems Holdings: Interim Results for the six month period ended 30 September 2016 73
  • 6.36 Nov 01, 2016: Oxford Immunotec Reports Third Quarter 2016 Financial Results 73
  • 6.37 Nov 01, 2016: Illumina Reports Full Financial Results for Third Quarter of Fiscal Year 2016 75
  • 6.38 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 76
  • 6.39 Oct 21, 2016: Immunodiagnostic Systems Holdings: H1 Trading Update 79
  • 6.40 Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results 81
  • 6.41 Oct 10, 2016: Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016 83
  • 6.42 Sep 12, 2016: EKF Diagnostics Holdings: Half-year Report 84

7 Appendix 87

  • 7.1 Methodology 87
  • 7.2 About GlobalData 90
  • 7.3 Contact Us 90
  • 7.4 Disclaimer 90

List of Tables

1.1 List of Tables

  • Table 1: Metabolite Chemistry Reagents - Pipeline Products by Stage of Development 7
  • Table 2: Metabolite Chemistry Reagents - Pipeline Products by Territory 8
  • Table 3: Metabolite Chemistry Reagents - Pipeline Products by Regulatory Path 9
  • Table 4: Metabolite Chemistry Reagents Companies - Pipeline Products by Stage of Development 10
  • Table 5: Metabolite Chemistry Reagents - Pipeline Products by Stage of Development 11
  • Table 6: A/C Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 12
  • Table 7: Folate Enzymatic Assay - Product Status 12
  • Table 8: Folate Enzymatic Assay - Product Description 12
  • Table 9: Advanced Liquid Logic Inc Pipeline Products & Ongoing Clinical Trials Overview 13
  • Table 10: Total Serum Biliruibin Multiplex Assay - Product Status 13
  • Table 11: Total Serum Biliruibin Multiplex Assay - Product Description 13
  • Table 12: Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 14
  • Table 13: ACE Alera Clinical Chemistry System - Neonatal Bilirubin Assay - Product Status 14
  • Table 14: ACE Alera Clinical Chemistry System - Neonatal Bilirubin Assay - Product Description 14
  • Table 15: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 16: BIL-Direct JG Fluitest - Product Status 16
  • Table 17: BIL-Direct JG Fluitest - Product Description 16
  • Table 18: BIL-Total JG Fluitest - Product Status 16
  • Table 19: BIL-Total JG Fluitest - Product Description 17
  • Table 20: BIL-Total VBM Fluitest - Product Status 17
  • Table 21: BIL-Total VBM Fluitest - Product Description 17
  • Table 22: BIL-Total WG Fluitest - Product Status 18
  • Table 23: BIL-Total WG Fluitest - Product Description 18
  • Table 24: BILD-DCA Fluitest - Product Status 18
  • Table 25: BILD-DCA Fluitest - Product Description 19
  • Table 26: BILT-DCA Fluitest - Product Status 19
  • Table 27: BILT-DCA Fluitest - Product Description 19
  • Table 28: CHOL - HDL Direct Fluitest - Product Status 20
  • Table 29: CHOL - HDL Direct Fluitest - Product Description 20
  • Table 30: CHOL - LDL Direct Fluitest - Product Status 20
  • Table 31: CHOL - LDL Direct Fluitest - Product Description 21
  • Table 32: CHOL - LDL Fluitest - Product Status 21
  • Table 33: CHOL - LDL Fluitest - Product Description 21
  • Table 34: CHOL CHOD-PAP Lyophilisat - Product Status 22
  • Table 35: CHOL CHOD-PAP Lyophilisat - Product Description 22
  • Table 36: CHOL Fluitest - Product Status 22
  • Table 37: CHOL Fluitest - Product Description 23
  • Table 38: Fluitest ALB-BCG - Product Status 23
  • Table 39: Fluitest ALB-BCG - Product Description 23
  • Table 40: Fluitest BIL - Direct Walters/Gerarde - Product Status 24
  • Table 41: Fluitest BIL - Direct Walters/Gerarde - Product Description 24
  • Table 42: Fluitest BIL T/D - Product Status 24
  • Table 43: Fluitest BIL T/D - Product Description 25
  • Table 44: Fluitest CHOL-HDL Phosphotungstic Acid/Magnesium Chloride - Product Status 25
  • Table 45: Fluitest CHOL-HDL Phosphotungstic Acid/Magnesium Chloride - Product Description 25
  • Table 46: Fluitest CREA - Kinetic - Product Status 26
  • Table 47: Fluitest CREA - Kinetic - Product Description 26
  • Table 48: Fluitest FE FZ - Product Status 26
  • Table 49: Fluitest FE FZ - Product Description 27
  • Table 50: Fluitest FRUC - Product Status 27
  • Table 51: Fluitest FRUC - Product Description 28
  • Table 52: Fluitest GLU GOD-PAP - Product Status 28
  • Table 53: Fluitest GLU GOD-PAP - Product Description 28
  • Table 54: Fluitest LA PAP - Product Status 29
  • Table 55: Fluitest LA PAP - Product Description 29
  • Table 56: GLU GOD - PAP Lyophilisat - Product Status 29
  • Table 57: GLU GOD - PAP Lyophilisat - Product Description 30
  • Table 58: HbA1 Ion Exchange Batch Assay - Product Status 30
  • Table 59: HbA1 Ion Exchange Batch Assay - Product Description 30
  • Table 60: HbA1c Micro Column Assay - Product Status 31
  • Table 61: HbA1c Micro Column Assay - Product Description 31
  • Table 62: Turbitex FER - Product Status 31
  • Table 63: Turbitex FER - Product Description 32
  • Table 64: Turbitex HbA1c/Hb Assay - Product Status 32
  • Table 65: Turbitex HbA1c/Hb Assay - Product Description 32
  • Table 66: BG Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 67: LipidDx - Product Status 33
  • Table 68: LipidDx - Product Description 33
  • Table 69: Genesis Detection Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 70: Rapid Home Test - HDL/LDL Cholesterol - Product Status 34
  • Table 71: Rapid Home Test - HDL/LDL Cholesterol - Product Description 34
  • Table 72: Healthmed Services Ltd. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 73: Glycated Albumin Test - Product Status 35
  • Table 74: Glycated Albumin Test - Product Description 35
  • Table 75: Instrumentation Laboratory Company Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 76: GEM Premier 4000 Analyzer - BUN - Product Status 36
  • Table 77: GEM Premier 4000 Analyzer - BUN - Product Description 36
  • Table 78: iXensor Co. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 79: Uric Acid Test - Product Status 37
  • Table 80: Uric Acid Test - Product Description 37
  • Table 81: Luminor Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 82: Next Generation PreVu LP Test - Product Status 38
  • Table 83: Next Generation PreVu LP Test - Product Description 38
  • Table 84: Ohmx Corp Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 85: Diagnostic Test - FAD Metabolite - Product Status 39
  • Table 86: Diagnostic Test - FAD Metabolite - Product Description 39
  • Table 87: Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 88: ADVIA 1800 Chemistry System - Creatinine Validity Test - Product Status 40
  • Table 89: ADVIA 1800 Chemistry System - Creatinine Validity Test - Product Description 40
  • Table 90: The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 91: Albumin Urine SPAplus Kit - Product Status 41
  • Table 92: Albumin Urine SPAplus Kit - Product Description 41
  • Table 93: Versantis AG Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 94: TS-01 - Product Status 42
  • Table 95: TS-01 - Product Description 42
  • Table 96: Glossary 89

List of Figures

1.2 List of Figures

  • Figure 1: Metabolite Chemistry Reagents - Pipeline Products by Stage of Development 7
  • Figure 2: Metabolite Chemistry Reagents - Pipeline Products by Territory 8
  • Figure 3: Metabolite Chemistry Reagents - Pipeline Products by Regulatory Path 9
Back to Top